Neuro-oncologist andrew brenner, m.d., ph.d. and barbara blouw, ph.d.

The addition of both dr. brenner and dr. blouw substantially expands plus internal expertise in key areas dr. brenner will maintain his academic commitments but will greatly contribute to plus' scientific and clinical efforts to develop targeted radiotherapeutics for central nervous system (cns) cancers dr. blouw is an expert in cns tumor biology and in the diagnosis of neoplasms of the cerebrospinal fluid austin, texas, april 09, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq:  pstv ) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced that andrew brenner, m.d., ph.d. (professor-research, departments of medicine, neurology, and neurosurgery & s & b kolitz/ctrc-zachry endowed chair neuro-oncology research, mays cancer center at ut health san antonio) has formally joined the company in a part-time capacity.
pstv Ratings Summary
pstv Quant Ranking